Meseclazone
Meseclazone (W2395; NSC297623) exhibits inhibitory potency of secondary phase ADP aggregation. Meseclazone possesses anti-inflammatory, analgesic and antipyretic activity.
Product Specifications
CAS Number
29053-27-8
Product Name Alternative
W2395; NSC297623
UNSPSC
12352005
Hazard Statement
H302-H315-H319-H335
Target
P2Y Receptor
Type
Reference compound
Related Pathways
GPCR/G Protein
Applications
COVID-19-immunoregulation
Field of Research
Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/NSC297623.html
Solubility
10 mM in DMSO
Smiles
O=C1N(OC(C)C2)C2OC3=CC=C(Cl)C=C13
Molecular Formula
C11H10ClNO3
Molecular Weight
239.66
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501
References & Citations
[1]Diamantis W, et al. Meseclazone, 5-chlorosalicylic acid and acetylsalicylic acid. Comparison of their effects on in vitro and ex vivo platelet aggregation. Thromb Haemost. 1978 Aug 31;40 (1) :24-36.|[2]Diamantis W, et al. Antagonism by meseclazone and other nonsteroidal anti-inflammatory drugs of bradykinin-induced bronchospasm. Pharmacology. 1982;24 (4) :243-7.
Shipping Conditions
Room temperature
Scientific Category
Reference compound1
Clinical Information
No Development Reported
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
GTR10426599 96 Well
Chicken Collagen Alpha 1 (XXI) chian (COL21A1) ELISA kit
Sign In for Pricing
View Details